Company Overview and News
The index made strong gains this week as investors shrugged off trade tensions. Trump’s decision to impose fresh tariffs on $200 billion of Chinese imports did weigh on investors. But the recent raft of positive economic data helped investors focus on broader fundamentals. Financials gained after yields on U.S. government bonds surged substantially. Tech majors also defied tariff worries to post strong gains.
BAC GS GLSSP DIS JBK BAC PFZ C GSC TFG MA PFIZER GSJ V MSFT GJS 500680 PFE
So we are going to get started, again. For those joining us on the webcast, again, I’m Craig Maurer of Anonymous. I run the Payments team here. We are lucky today to have Craig Vosburg from Mastercard. He is President of North America for the company. Thanks for joining us.
Mastercard Incorporated (MA - Free Report) and JAGGAER have entered into a partnership to jointly launch Mastercard Track, a new trade platform designed to streamline and boost its global commercial business interactions. This new platform targets the international B2B (Business to Business) market, which still works manually and incurs around $500 billion of annual administrative expenses. Track is powered by an array of Mastercard innovation and B2B assets, such as account-to-account and card payment solutions, data analytics, fraud management, payment gateway services, etc.
UNP MA WEX CATM EVTC
Visa Inc. (V - Free Report) , Mastercard Incorporated (MA - Free Report) , along with banks including JPMorgan Chase & Co. (JPM - Free Report) , Citigroup Inc. (C - Free Report) and Bank of America Corp. would pay merchants about $6.5 billion on account of Payment Card Interchange Fee and Merchant Discount Antitrust Litigation.
C UNP MA V CGBBW
2018-09-19 investorplace - 1
One of the more popular strategies among investors today is to seek out “home runs.” These are lesser-known companies that have tremendous upside potential, but carry the risk of collapsing should business prospects go awry. While a balanced portfolio allows for some speculation, now is also a great time to consider S&P 500 stocks.
LMT HD EA FB UPS MA DRI FDX BBY HOG GT V AMZN CVX RTN ABBV HPQ MO
2018-09-19 investorplace - 2
Workers in their 30s and 40s often find themselves in tricky situations, career-wise. They’re certainly beyond their trainee days, but not yet in positions only awarded to employees with a wealth of experience and proven acumen. It’s in this time of life when workers find themselves on a clear path to some sort of senior position, or realize it’s just not going to happen.
QRVO MA PYPL AMD NVDA WMT ADBE AMZN AMT MRK GOOGL MSFT CAH INTC
NEW YORK (Reuters) - Wall Street bounced back on Tuesday, led by gains in consumer discretionary, technology and industrial stocks as investors shrugged off escalating trade rhetoric between the United States and China.
GIS FIT V NKE BOE AAPL MA BA
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
C MA V CGBBW SBUX
NEW YORK (Sept 18): Visa Inc, Mastercard Inc, and a number of US banks on Tuesday agreed to pay US$6.2 billion to settle a long-running lawsuit brought by merchants over the fees they pay when they accept card payments.
V COST MA
Sept 18 (Reuters) - Visa Inc, Mastercard Inc, and a number of banks on Tuesday agreed to pay $6.2 billion to settle a long-running lawsuit brought by merchants over the fees they pay when they accept card payments.
(Reuters) - Visa Inc (V.N), Mastercard Inc (MA.N), and a number of banks on Tuesday agreed to pay $6.2 billion to settle a long-running lawsuit brought by merchants over the fees they pay when they accept card payments.
Visa Inc , Mastercard Inc , and a number of banks on Tuesday agreed to pay US$6.2 billion to settle a long-running lawsuit brought by merchants over the fees they pay when they accept card payments.
U.S. stock-index futures were slightly higher on Tuesday, though investors continued to monitor the latest development on the trade-policy front, which has recently shown signs of escalating.
GIS V AZO OCLCF MA ORCL
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to MA / MasterCard Incorporated on message board site Silicon Investor.
as of ET